Landes Bioscience www.landesbioscience.com

Supplemental Material to:

Kenichiro Doi, Qiang Liu, Krishne Gowda, Brian M Barth, David Claxton, Shantu Amin, Thomas P Loughran Jr, and Hong-Gang Wang

Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression

Cancer Biology & Therapy 2014; 15(8)
http://dx.doi.org/10.4161/cbt.29186

http://www.landesbioscience.com/journals/cbt/article/29186/



Figure S1. Potency of (+), (–), and racemic maritoclax in U937 (**A**) and Mcl-1-IRES-Bim K562 cells (**B**) in viability assays.



Figure S2. Representative colonies in vehicle-treated colony formation assay of primary mouse bone marrow, taken with the Olympus DP20 and the cellSens Standard software at 10× magnification.

Table S1. Primary human AML sample characteristics

Patient Case #	WBC *(×1000/μL)*	Blast *(%)*	NPM1 Mutation	FLT3-ITD Mutation	Cytogenetics
555	15.78	70	ND	ND	t(9;11)
559	66.6	66	-	-	Complex
477	122.3	78	-	-	del(15)(q13q15)
574	107.7	58	+	+	Normal

Table S2. The EC50 of MEF, HEK293, and HeLa cells to maritoclax in viability assays

	EC_{50} (μM)		
	Maritoclax	**ABT-737**	**Daunorubicin**
MEF	18.1*	> 50*	1.75*
HEK293	> 50*	> 50*	41.2*
HeLa	> 50	49.4	0.33

*Cells were treated with the indicated compounds for 24 h.